SEC 13F Intelligence

Managers / Q3 2025 · view latest →

SYQUANT CAPITAL SAS

CIK 0001766392 · 25 AVENUE KLEBER, PARIS, I0, 75116 · 0033142569307

Reported Value
$348M
Q3 2025
Positions
17
Filings on Record
32
2019–present window
Filed
Oct 28, 2025
original filing

Summary

Syquant Capital Sas reported $348M in U.S.-listed holdings across 17 positions for Q3 2025.

The portfolio is heavily concentrated: VRNA alone accounts for 37.0% of reported value.

Compared with Q2 2025, the fund opened 13 new positions and exited 10.

Portfolio Metrics

Turnover
+63.8%
vs prior filed quarter
Top-10 Concentration
+98.7%
share of reported value
Largest Position
+37.0%
Verona Pharma
New / Exited
13 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $117MQ4 ’18Q1 ’19: $258MQ2 ’19: $312MQ3 ’19: $365MQ4 ’19: $194MQ4 ’19Q1 ’20: $407MQ2 ’20: $215MQ3 ’20: $196MQ4 ’20: $387MQ4 ’20Q1 ’21: $386MQ2 ’21: $83MQ3 ’21: $164MQ4 ’21: $262MQ4 ’21Q1 ’22: $195MQ2 ’22: $90MQ3 ’22: $165MQ4 ’22: $41MQ4 ’22Q1 ’23: $43MQ2 ’23: $138MQ3 ’23: $255MQ4 ’23: $22MQ4 ’23Q1 ’24: $64MQ2 ’24: $10MQ3 ’24: $27MQ4 ’24: $70MQ4 ’24Q1 ’25: $141MQ2 ’25: $302MQ3 ’25: $348MQ4 ’25: $817MQ4 ’25Q1 ’26: $640MQ2 ’26: $447Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 58.1%ADR: 37.0%Other: 4.4%US DOMESTIC: 0.6%
  • Common Stock · 58.1% · $202M
  • ADR · 37.0% · $129M
  • Other · 4.4% · $15M
  • US DOMESTIC · 0.6% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
VRNAVerona Pharma PLCNEW+1.21M1.21M+$129M$129M
89BIONEW+2.59M2.59M+$38M$38M
IPGInterpublic Grp Common StockNEW+854.3K854.3K+$24M$24M
Informatica Inc cl ANEW+537.8K537.8K+$13M$13M
Cantor Equity Prtners IV IncNEW+500.0K500.0K+$5M$5M
WNS Holdings LtdNEW+48.7K48.7K+$4M$4M
CRHCRH PLC - NYSE listingNEW+23.8K23.8K+$3M$3M
M3-Brigade Acquisition VI CorpNEW+200.0K200.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2025

17 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1VRNAVerona Pharma PLChistory →SPONSORED ADS37.01%$129M1.21M
2KELKellanovahistory →COM35.62%$124M1.51M
389BIOCOM10.94%$38M2.59M
4IPGInterpublic Grp Common Stockhistory →COM6.84%$24M854.3K
5Informatica Inc cl ACOM CL A3.83%$13M537.8K
6Cantor Equity Prtners IV IncSHS CL A1.46%$5M500.0K
7WNS Holdings LtdCOM SHS1.07%$4M48.7K
8CRHCRH PLC - NYSE listingORD0.82%$3M23.8K
9M3-Brigade Acquisition VI CorpUNIT 08/18/20300.58%$2M200.0K
10AIRBNB INCNOTE 3/10.56%$2M2.00M
11American Exceptionalism AcquisORD CL A0.39%$1M125.0K
12Pioneer Acquisition I CorpUNIT 06/16/20300.32%$1M110.0K
13MERUS BVCOM0.32%$1M11.7K
14Wen Acquisition CorpUNIT 05/16/20300.07%$261,00025.0K
15Trailbrazer Acquisition CorpUNIT 08/21/20300.07%$256,00025.0K
16Bain Capital GSS Investment CoUNIT 99/99/99990.06%$202,00020.0K
171RT Acquisition CorpUNIT 06/26/20300.03%$105,00010.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q2 2026$447M38Jul 9, 202613F-HRchanges · EDGAR ↗
Q1 2026$640M40Apr 10, 202613F-HRchanges · EDGAR ↗
Q4 2025$817M37Jan 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$348M17Oct 28, 202513F-HRchanges · EDGAR ↗
Q2 2025$302M14Jul 18, 2025RESTATEMENTchanges · EDGAR ↗
Q1 2025$141M14Apr 23, 202513F-HRchanges · EDGAR ↗
Q4 2024$70M6Jan 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$27M5Oct 4, 202413F-HRchanges · EDGAR ↗
Q2 2024$10M5Jul 10, 202413F-HRchanges · EDGAR ↗
Q1 2024$64M6Apr 9, 202413F-HRchanges · EDGAR ↗
Q4 2023$22M7Jan 10, 202413F-HRchanges · EDGAR ↗
Q3 2023$255M9Oct 12, 202313F-HRchanges · EDGAR ↗
Q2 2023$138M11Jul 10, 202313F-HRchanges · EDGAR ↗
Q1 2023$43M7Apr 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$41M14Jan 17, 202313F-HRchanges · EDGAR ↗
Q3 2022$165M25Oct 11, 202213F-HRchanges · EDGAR ↗
Q2 2022$90M32Jul 8, 202213F-HRchanges · EDGAR ↗
Q1 2022$195M35Apr 7, 202213F-HRchanges · EDGAR ↗
Q4 2021$262M43Jan 12, 202213F-HRchanges · EDGAR ↗
Q3 2021$164M42Oct 14, 202113F-HRchanges · EDGAR ↗
Q2 2021$83M41Jul 14, 202113F-HRchanges · EDGAR ↗
Q1 2021$386M53Apr 20, 202113F-HRchanges · EDGAR ↗
Q4 2020$387M81Feb 5, 202113F-HRchanges · EDGAR ↗
Q3 2020$196M62Oct 21, 202013F-HRchanges · EDGAR ↗
Q2 2020$215M23Aug 5, 202013F-HRchanges · EDGAR ↗
Q1 2020$407M18Apr 14, 202013F-HRchanges · EDGAR ↗
Q4 2019$194M16Jan 8, 202013F-HRchanges · EDGAR ↗
Q3 2019$365M17Oct 17, 201913F-HRchanges · EDGAR ↗
Q2 2019$312M14Jul 5, 201913F-HRchanges · EDGAR ↗
Q1 2019$258M15Apr 12, 201913F-HRchanges · EDGAR ↗
Q4 2018$117M11Feb 4, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.